Hostname: page-component-8448b6f56d-qsmjn Total loading time: 0 Render date: 2024-04-23T07:25:31.377Z Has data issue: false hasContentIssue false
  • English
  • Français

Managing bipolar disorder during pregnancy and lactation: is there a safe and effective option?

Published online by Cambridge University Press:  16 April 2020

Pierre Thomas  and
W. Emanuel Severus
Pierre Thomas*
Affiliation:
Psychiatry Clinic, University of Lille 2, 6, Rue du Pr. Laguesse, 5903 Lille Cedex, France
W. Emanuel Severus
Affiliation:
Department of Psychiatry, Ludwig-Maximilians University, Nussbaumstrasse 7, 80336 Munich, Germany
*
*Corresponding author. pthomas@chru-lille.fr (R Thomas).
Get access

Extract

Bipolar disorder is a serious psychiatric illness that usually emerges during adolescence or early adulthood, and patients are likely to experience recurrent episodes throughout their lives. The treatment of bipolar disorder is complicated by the difficulty in distinguishing between subtly different disease subtypes (bipolar I, bipolar II, rapid cycling and mixed episodes), each of which is associated with a different probability of treatment success. Furthermore, physicians are faced with an array of treatment options that includes mood stabilisers, antidepressants, and typical and atypical antipsychotics.

Type
Research Article
Information
European Psychiatry , Volume 18 , Issue S1 , December 2003 , pp. 3s - 8s
Copyright
Copyright © European Psychiatric Association 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Grof, PRobbins, WAida, MBerghoefer, AVojtechovsky, MNilsson, AProtective effect of pregnancy in women with lithium-respon sive bipolar disorder. J Affect Dis 2000; 61: 31–39.CrossRefGoogle Scholar
Viguera, ACNonacs, RCohen, LSTondo, LMurray, ABaldessarini, RJRisk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psy 2000:157: 179–184.CrossRefGoogle ScholarPubMed
Freeman, MPSmith, KWFreeman, SAMcElroy, SLKmetz, GEWright, RThe impact of reproductive events on the course of bipolar disorder in women. J Clin Psy 2002; 63: 284–7.CrossRefGoogle ScholarPubMed
Cohen, LSSichel, DARobertson, LMHeckscher, ERosenbaum, JFPostpartum prophylaxis for women with bipolar disorder. Am J Psy 1995: 152: 1641–5.Google ScholarPubMed
Viguera, ACCohen, LSBaldessarini, RJNonacs, RManaging bipolar disorder during pregnancy: weighing the risks and benefits. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 2002; 47: 426–36.Google Scholar
Ward, RKZamorski, MABenefits and risks of psychiatric medications during pregnancy. Am Fam Phys 2002; 66: 629–636, 639.Google ScholarPubMed
Viguera, ACCohen, LSBouffard, SWhitfield, THBaldessarini, RJReproductive decisions by women with bipolar disorder after prepregnancy psychiatric consultation. Am J Psy 2002; 159: 2102–4.CrossRefGoogle ScholarPubMed
Fafouti, MPaparrigopoulos, TLiappas, JMantouvalos, VTypaldou, RChristodoulou, GMood disorder with mixed features due to vitamin B12 and folate deficiency. Gen Hosp Psy 2002; 24: 106–9.CrossRefGoogle ScholarPubMed
Coppen, ABailey, JEnhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo-controlled trial. J Affect Dis 2002; 60: 121–30.CrossRefGoogle Scholar
Coppen, AChaudhry, SSwade, CFolic acid enhances lithium prophylaxis. J Affect Dis 1986; 10: 9–13.CrossRefGoogle ScholarPubMed
Hibbeln, JRSeafood consumption, the DHA content of mothers’milk and prevalence rates of postpartum depression: a cross-national, eco logical analysis. J Affect Dis 2002; 69: 15–29.CrossRefGoogle Scholar
Stoll, ALSeverus, WEFreeman, MPRueter, SZboyan, HADiamond, EOmega 3 fatty acids in bipolar disorder. A preliminary double-blind, placebo-controlled trial. Arch Gen Psy 1999, 56: 407–12.CrossRefGoogle ScholarPubMed
Benedetti, FColombo, CBarbini, BCampori, ESmeraldi, EMorning sunlight reduces length of hospitalization in bipolar depression. J Affect Dis 2001; 62: 221–3.CrossRefGoogle ScholarPubMed
Oren, DAWisner, KLSpinelli, MEpperson, CNPeindl, KSTerman, JSet al.An open trial of morning light therapy for treatment of antepartum depression. Am J Psy 2002; 159: 666–9.CrossRefGoogle Scholar
Cohen, LSFriedman, JMJefferson, JWJohnson, EMWerner, MLA réévaluation of risk of in utero exposure to lithium. JAMA 1994; 271: 146–50.CrossRefGoogle ScholarPubMed
Schou, MWhat happened to the lithium babies? A follow-up study of children born without malformations. Acta Psy Scan 1976; 54: 193–7.CrossRefGoogle Scholar
Viguera, ACNeurobehavioral outcome following lithium exposure: what happens to lithium babies, in American Psychiatric Association. New Orleans, Louisianna: 2001.Google Scholar
American Academy of Pediatrics Committee on Drugs. Use of psyh-coactive medication during pregnancy and possible effects on the fetus and newborn. Pediatrics 2000; 105: 880–7.CrossRefGoogle Scholar
Iqbal, MMSohhan, TMahmud, SZThe effects of lithium, valproic acid and carbamazepine during pregnancy and lactation. Clin Tox 2001;39:381–92.Google ScholarPubMed
Holmes, LBHarvey, EACoull, BAHuntington, KBKhoshbin, SHayes, AMet al.The teratogenicity of anticonvulsant drugs. New England J Med 2001; 344: 1132–8.CrossRefGoogle ScholarPubMed
Webster, WSHowe, AMLipson, AHThe role of vitamin K in prenatal development. Teratology 1995; 15: 285.Google Scholar
Moore, SJTurnpenny, PQuinn, AGlover, SLloyd, DJMontgomery, Tet al.A clinical study of 57 children with fetal anticonvulsant syndromes. J Med Gen 2000, 37: 489–97.CrossRefGoogle ScholarPubMed
Reinisch, JMSanders, SAMortensen, ELRubin DB In utero exposure to phénobarbital and intelligence deficits in adult men. JAMA 1995; 274: 1518–25.CrossRefGoogle ScholarPubMed
Scolnik, DNulman, IRovet, JGladstone, DCzuchta, DGardner, HAet al.Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA 1994; 271. 767–70.CrossRefGoogle ScholarPubMed
Trixler, MTenyi, TAntipsychotic use in pregnancy. What are the best treatment options? Drug Safety 1997; 16; 403–10.CrossRefGoogle ScholarPubMed
Altshuler, LLCohen, LSzuba, MPBurt, VKGitlin, MMintz, JPharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psy 1996; 153: 592–606.Google ScholarPubMed
Ernst, CLGoldberg, JFThe reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. J Clin Psy 2002; 63: 42–55.Google ScholarPubMed
Dev, VKrupp, PThe side effects and safety of clozapine. Rev Con-temp Pharma 1995; 6: 197–208.Google Scholar
Goldstein, DJCorbin, LAFung, MCLanzapine-exposed pregnancies and lactation: early experience J Clin Psycho 2000; 20: 399–403.CrossRefGoogle ScholarPubMed
Ericson, AKallen, BW, BEDelivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharma 1999; 55: 503–8.CrossRefGoogle ScholarPubMed
Nulman, IRovet, JStewart, DEWolpin, JGardner, HATheis, JGet al.Neurodevelopment of children exposed m utero to antidepressant drugs. N Engl J Med 1997; 336: 258–62.CrossRefGoogle Scholar
Kulin, NAPastuszak, ASage, SR Schick-Boschetto, BSpivey, GFeldkamp, Met al.Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors. A prospective controlled multicenter study JAMA 1998; 279: 609–10.CrossRefGoogle ScholarPubMed
Lumley, JWatson, LWatson, MBower, CPericonceptual supplementation with folate and/or multivitamins for preventing neural tube defects. Cochrane Database Systematic Reviews 2001; 3: CD001056.CrossRefGoogle Scholar
Samrén, EBvan Duijn, CMKoch, SHulesmaa, VKKlepel, HBardy, AHet al.Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint european prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997:38: 981–90.CrossRefGoogle ScholarPubMed
Miller, LJUse of electroconvulsive therapy during pregnancy. Hosp Com Psy 1994;45:444–50.Google ScholarPubMed
American Academy of Pediatrics: Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics 2001; 108: 776–89.CrossRefGoogle Scholar
Thomsen, KSchou, MAvoidance of lithium intoxication: advice based on knowledge about the renal lithium clearance under various circumstances. Pharmacopsychiatry 1999; 32: 83–6.CrossRefGoogle ScholarPubMed
Chaudron, LHJefferson, JWMood stabilizers during breastfeeding: A review. J Clin Psy 2000; 61: 79–90.Google ScholarPubMed
Barnas, CBergant, AHummer, MSaria, AFleischhacker, WWClozapine concentrations in maternal and fetal plasma, amniotic fluid and breast milk. Am J Psy 1994; 151: 945.Google ScholarPubMed
Misri, SKostaras, XBenefits and risks to mother and infant of drug treatment for postnatal depression. Drug Safety 2002; 25: 903–11.CrossRefGoogle ScholarPubMed
Hendrick, VStowe, ZNAltshuler, LLMintz, JHwang, SHostetter, Aet al.Fluoxetine and norfluoxetine concentrations in nursing infants and breast milk. Biol Psy 2001; 50: 775–82.CrossRefGoogle ScholarPubMed
Epperson, CNCzarkowski, KAWard-O’Brien, DWeiss, EGueorguieva, RJatlow, Pet al.Maternal sertraline treatment and serotonin transport in breast-feeding mother-infant pairs. Am J Psy 2001; 158: 1631–7.CrossRefGoogle ScholarPubMed
Schmidt, KOlesen, OVJensen, PNCitalopram and breast-feeding: serum concentration and side effects in the infant. Biol Psy 2000; 47. 164–5CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.